XML 44 R35.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Acquisitions - Additional Information (Details) $ / shares in Units, $ in Millions | 1 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | ---
Jul. 31, 2021 USD ($) shares | Feb. 28, 2021 USD ($) Milestone | Sep. 30, 2016 USD ($) $ / shares | Dec. 31, 2021 USD ($) | Sep. 30, 2022 USD ($) | Jul. 01, 2021 USD ($) | Aug. 31, 2017 USD ($)
Humabs |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Estimated fair value of contingent consideration |  |  |  | $ 17.1 | $ 29.6 |  |
Humabs | HBV Product |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Additional consideration payable upon achievement of specified milestone events, maximum |  |  |  |  |  |  | $ 135.0
Estimated fair value of contingent consideration |  |  |  |  | 29.6 |  |
Humabs | Another Product |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Additional consideration payable upon achievement of specified milestone events, maximum |  |  |  |  |  |  | $ 105.0
Humabs | SARS-CoV-2 Product |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Regulatory milestones achieved |  |  |  | 35.0 |  |  |
Sales milestone achieved |  |  |  | $ 60.0 |  |  |
TomegaVax |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Minimum common stock conversion price for milestone payments consideration | $ / shares |  |  | $ 90 |  |  |  |
Asset acquisition contingent consideration liability |  |  |  |  | 1.1 |  |
Common stock shares Issued for milestone payment| shares | shares | 42,737 |  |  |  |  |  |
Value of common stock shares Issued for milestone payment | $ 1.9 |  |  |  |  |  |
Payment made for asset acquisition milestone |  |  |  |  |  | $ 8.1 |
TomegaVax | Clinical Development [Member] |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Minimum common stock conversion price for milestone payments consideration | $ / shares |  |  | $ 45 |  |  |  |
TomegaVax | TomegaVax Letter Agreement |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Milestone payments aggregate amount payable, maximum |  |  | $ 30.0 |  |  |  |
Minimum common stock conversion price for milestone payments consideration | $ / shares |  |  | $ 45 |  |  |  |
Milestone payments related terms |  |  | the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $30.0 million if the per-share price of the Company’s publicly traded common stock, or implied price per share of the Company’s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Company’s clinical development at the time of the relevant event triggering the payment. |  |  |  |
Number of milestones achieved | Milestone |  | 1 |  |  |  |  |
Asset acquisition contingent consideration liability |  | $ 10.0 |  |  | $ 1.1 |  |
TomegaVax | Maximum |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Remaining payment for asset acquisition milestone, maximum |  |  |  |  |  | $ 20.0 |

X
- Definition Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 30 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 30 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of liability recognized from contingent consideration in asset acquisition, classified as current. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 15 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492 + Details
Name: | us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition For contingent consideration arrangements recognized in connection with an asset acquisition, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References No definition available. + Details
Name: | vir_AssetAcquisitionMilestonePaymentAggregate
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Asset acquisition number of milestones achieved related to contingent consideration. + References No definition available. + Details
Name: | vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration
Namespace Prefix: | vir_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business combinations additional consideration payable upon achievement of specified events. + References No definition available. + Details
Name: | vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Total number of common shares issued for milestone payment. + References No definition available. + Details
Name: | vir_CommonStockSharesIssuedForMilestonePaymentShares
Namespace Prefix: | vir_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Milestone payments related terms description. + References No definition available. + Details
Name: | vir_MilestonePaymentsRelatedTermsDescription
Namespace Prefix: | vir_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum common stock conversion price for milestone payments consideration. + References No definition available. + Details
Name: | vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration
Namespace Prefix: | vir_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment made for asset acquisition milestone. + References No definition available. + Details
Name: | vir_PaymentMadeForAssetAcquisitionMilestone
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Regulatory milestones achieved during the reporting period. + References No definition available. + Details
Name: | vir_RegulatoryMilestonesAchieved
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in connection with an asset acquisition, this element represents an estimate of the high-end of the potential range (undiscounted) of the remaining consideration which may be paid. + References No definition available. + Details
Name: | vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Sales milestones achieved during the reporting period + References No definition available. + Details
Name: | vir_SalesMilestonesAchieved
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_HepatitisBVirusProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_AnotherProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_SARSCoV2ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=vir_TomegaVaxIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vir_ClinicalDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_LetterAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |